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Abstract: The treatment of metastatic breast cancer remained a challenge despite the recent
breakthrough in the immunotherapy regimens. Here, we addressed the multidimensional
immunophenotyping of 4T1 metastatic breast cancer by the state-of-the-art single cell mass cytometry
(CyTOF). We determined the dose and time dependent cytotoxicity of cisplatin on 4T1 cells by the
xCelligence real-time electronic sensing assay. Cisplatin treatment reduced tumor growth, number of
lung metastasis, and the splenomegaly of 4T1 tumor bearing mice. We showed that cisplatin inhibited
the tumor stroma formation, the polarization of carcinoma-associated fibroblasts by the diminished
proteolytic activity of fibroblast activating protein. The CyTOF analysis revealed the emergence of
CD11b+/Gr-1+/CD44+ or CD11b+/Gr-1+/IL-17A+ myeloid-derived suppressor cells (MDSCs) and
the absence of B220+ or CD62L+ B-cells, the CD62L+/CD4+ and CD62L+/CD8+ T-cells in the spleen
of advanced cancer. We could show the immunomodulatory effect of cisplatin via the suppression of
splenic MDSCs and via the promotion of peripheral IFN-γ+ myeloid cells. Our data could support
the use of low dose chemotherapy with cisplatin as an immunomodulatory agent for metastatic triple
negative breast cancer.
Keywords: single cell mass cytometry; metastatic breast cancer; myeloid-derived suppressor
cells; immunophenotyping
1. Introduction
The role of the tumor microenvironment, the interaction of cancer cells with the extracellular
matrix, endothelial cells, cancer-associated fibroblasts, and leukocytes in the tumor stroma have been
increasingly considered as a milestone in cancer development, especially in the last decade [1,2].
The deeper understanding of the disturbances in the regulation and activation of the immune system in
cancer resulted in the advancement of anti-cancer therapies, such as the immune checkpoint blockade
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(ICB) [3]. However, the treatment of poorly immunogenic and metastasizing tumors remained
a challenge.
Here, we focus on female breast cancer since it is the most frequent cancer in women and
still the deadliest cancer type between the ages of 20–49 years old in contrast to the achievements
in early diagnostics and therapeutics [4,5]. In our work the murine mammary carcinoma of the
BALB/c mice, the syngeneic 4T1 was studied [6]. The 4T1 model is among the few murine triple
negative breast cancer (TNBC) models that spontaneously metastasize to sites affected in human
breast cancer (e.g., lung) in an immunocompetent host [7]. Orthotopic transplantation of 4T1 cells
offers a relevant tumor model to study efficacy of drug candidates or immune therapy regimens [8].
Previously, we showed the tumor promoting effect of mesenchymal stem cell (cancer associated
fibroblast)-derived galectin-1 in the 4T1 model [9], and later on we screened an anti-cancer compound
library of imidazo[1-2-b]pyrazole-7-carboxamides in both two- and three-dimensional cell cultures of
4T1 cells [10,11].
We have previously reviewed how cancer-related chronic inflammation can lead to the generation
of immature myeloid-derived suppressor cells (MDSCs) and to the alternative polarization of
tumor-associated macrophages (TAMs) [12], which manifests autonomously in the 4T1 breast cancer
model [13,14]. It has been shown that the granulocytic MDSCs support metastases by suppressing
CD8+ T-cells in the 4T1 breast tumor model [15]. It was also recently shown that 4T1 cells shape
immune responses with an increase of splenic CD11b+ cells to promote cancer growth in an Shb (SRC
homology-2 domain protein B) dependent manner [16]. The 4T1 tumor cells are poorly immunogenic
and refractory to immune therapies, although the combination of anti-PD-1, anti-CTLA-4 ICB with
epigenetic modulators could have a therapeutic benefit curing more than 80% of 4T1 tumor bearing mice
via eliminating MDSCs [17]. We have previously reviewed strategies targeting these myeloid-derived
suppressors cells or tumor associated macrophages to combat cancer [18]. Here, the traditional
chemotherapeutic agent, the DNA crosslinker cisplatin was used, since cisplatin and platinum-based
chemoterapeutics are in the clinical routine as first line treatment option in several cancers such as lung,
bladder, ovarian and metastatic breast cancer [19]. Recent studies have shown the immune induction by
cisplatin in human TNBC (the TONIC trial NCT02499367) [20], or in murine carcinoma models showing
enhanced sensitivity to ICB therapy in combination with cisplatin treatment but these studies did not
deal with immunophenotyping of the myeloid compartment [21,22]. The beneficial effect of cisplatin
on the course of 4T1 tumor development was shown recently in combination with metformin or
bromelain [23,24], but these studies also did not address the characterization of the immunophenotype.
To the best of our knowledge our study is the first, where mass cytometry, a multidimensional
single cell technology with computational data analysis was carried out in order to reveal the
immunophenotype of 4T1 murine triple negative breast carcinoma and the effect of cisplatin treatment
on the splenic and circulating immune compartments.
2. Results
2.1. Real-Time Monitoring of 4T1 Cell Viability Hampered by Cisplatin
Determination of the half maximal inhibitory concentration, the IC50 of cisplatin on 4T1 cells was
carried out using the real-time electronic sensing xCelligence system [25]. The detected impedance is
proportional with the percentage of adhered living cells to the gold coated plate and the decline in
the normalized cell index corresponds to hampered cell viability (Figure 1). The effect of cisplatin on
viability was followed for 120 h after treatment in every 15 min (former studies reported endpoint
assays with cisplatin on 4T1 cells). The IC50 values were as follows 36.74 µM at 24 h, 7.608 µM at 48 h,
6.962 µM at 72 h, 4.128 µM at 96 h, and 3.995 µM at 120 h (Figure S1).
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Figure 1. Real-time monitoring of 4T1 cell viability hampered by cisplatin. The 4T1 cells were seeded
and the baseline impedance was recorded for 48 h. After that 48 h culturing treatment with 11.111 µM,
33.333 µM, or 100 µM cisplatin reduced viability of 4T1 cells on a time and dose dependent manner.
The corresponding dose-response curves with the half maximal inhibitory concentration (IC50) values
can be found in Figure S1.
2.2. Cisplatin Treatment Reduced 4T1 Tumor Growth, the Number of Lung Metastatic Nodules and the Weight
of the Spleen
The syngeneic BALB/c mice were orthotopically transplanted with 4T1 breast cancer cells in order
to establish the animal model for the addressed immunophenotyping. Tumor growth was monitored
daily. All mice treated with cisplatin showed markedly reduced tumor growth compared to untreated
4T1 tumor bearing mice represented by the average tumor volume of 102 mm3 versus (vs.) 1481 mm3
on the 21st day (Figure 2A). On the 23rd day mice were euthanized for immunophenotyping and the
weight of the tumors (Figure 2B), the number of metastatic nodules (macrometastasis) on the lungs
(Figure 2C), and the weight of the spleens were measured (Figure 2D).
The average weight of the tumors was reduced by almost 90% due to cisplatin treatment,
namely 426.4 ± 110.1 mg (mean ± SEM) in the cisplatin treated 4T1 tumorous mice vs. 3087 ± 356 mg
in the untreated 4T1 tumor bearing mice (Figure 2B). The development of metastatic nodules on the
surface of the lungs were also inhibited by cisplatin, the average number of lung macrometastasis were
as follows: 0.42 ± 0.23 in cisplatin treated vs. 3.25 ± 0.524 in untreated 4T1 tumorous mice (Figure 2C).
Splenomegaly is one sign of myeloid cell expansion due to cancer related inflammation in tumor
bearing hosts [26]. Cisplatin treatment suppressed the enlargement of the spleen as spleen weights
were 143.04 ± 19.25 mg, 843.59 ± 38.69 mg, 123.91 ± 26.08 mg, in the naive, 4T1 tumor bearing and
cisplatin treated 4T1 tumor bearing mice, respectively (Figure 2D).
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Figure 2. Cisplatin treatment reduced 4T1 tumor growth, the number of lung metastatic nodules and
the weight of the spleen. The 4T1 cells (1.2 × 105) were transplanted by the injection into the mammary
fat pad of BALB/c mice (n = 12). Tumor growth was monitored daily (A). On the 23rd day mice were
euthanized and the weight of the tumors (B), the number of metastatic nodules on the lungs (C), and the
weight of the spleens were measured (D). Individual values and arithmetic mean values of the samples
± standard error of the mean (SEM) are plotted, statistical significance was set to *** p < 0.001.
2.3. Cisplatin Reduced the Activity of Fibroblast Activator Protein (FAP)
The increased activity of the prolyl endopeptidase FAP enzyme is a hallmark of the tumor stroma,
because of the accumulation and activation of cancer associated fibroblasts (CAFs). The FAP protease
activity either membrane bound on CAFs or solubilized, is proportional with the malignancy [27].
The activity of FAP enzyme was investigated, because it has been reported that the accumulation of
CAFs in the tumor stroma and their expression of FAP contributes to the chemoresistance to cisplatin in
carcinomas [28,29]. We have synthetized a peptide substrate (Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2,
Figure S2) in order to measure FAP activity in the plasma of naive, 4T1 tumor bearing and cisplatin
treated 4T1 tumorous mice (Figure 3).
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Figure 3. The proteolytic activity of the fibroblast activator protein (FAP) increased by the formation
of breast cancer, and was significantly decreased by cisplatin treatment. Area under the curve (AUC)
values from high pressure liquid chromatography (HPLC) analysis of the peptide digestion product 2
(Figure S2) were plotted. The results are shown as arithmetic mean values of the samples ± standard
error of the mean (SEM), statistical significance was set to *** p < 0.001, * p < 0.05.
FAP enzyme activity quantification was based on a direct measurement of a digested peptide
product with high pressure liquid chromatography (HPLC) (Figure S2). Fmoc-GP-Cox- was synthesized
(Avidin Ltd.) and used as a substrate, where “Cox” denotes for oxydized cysteine, namely, cysteic acid.
We used oxidized cysteine amino acid at position 3 in the peptide substrate of FAP, instead of unmodified
cysteine. In a preliminary experiment, we confirmed that the peptide with the oxidized cysteine
residue was the same or better substrate of FAP. Moreover, our improved peptide substrate is more
water soluble and after FAP digestion the dipeptide product (Fmoc-GP) could be better separated from
the intact substrate during HPLC analysis, then the unmodified version, enabling us more accurate
and sensitive quantification. We could detect FAP activity in the plasma of naive, 4T1 tumor bearing
and cisplatin treated 4T1 tumorous animals with the following average AUC (± SEM) values from
HPLC analysis: 518.5 ± 55.5 × 103, 1240.2 ± 77.9 × 103, 914.9 ± 71.7 × 103, respectively (Figure 3).
2.4. Single Cell Mass Cytometry (SCMC) Revealed the Immunophenotype of Breast Cancer Bearing Mice
2.4.1. Cisplatin Restored the Splenic Immunophenotype of 4T1 Tumor Bearing Mice
In order to investigate the immunophenotype of 4T1 breast cancer single cell mass cytometry
was performed with 24 antibodies in one single tube (see Table 1 in Section 4.5). We intended to
monitor the draining lymph nodes, bone marrow, spleen, and blood of the naive, 4T1 tumor bearing,
and cisplatin treated 4T1 tumorous animals. However, the orthotopic injection of 4T1 cells into the
mammary fat pad resulted in the outgrowth of the tumor mass in co-junction with the draining cervical
and axillary lymph nodes making them undetectable. Bone marrow staining showed homogenous
immature cells (little CD11+ Gr1+ elevation in tumor bearing hosts) excluding these samples from
further analysis. Our attention turned toward the spleen since it has been published in the seminal
paper of Bronte et al. that tolerance to tumor antigens develops in the spleen [30]. During the SCMC
analysis of the spleen CD45+ living singlets were gated and on these leukocytes the unsupervised and
multidimensional visualization of stochastic neighbor embedding (viSNE) analysis was performed
delineating the separate clouds of different main immune subsets (Figure 4) [31].
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Table 1. The list of the antibodies used for mass cytometry.
Target Clone Metal Tag
Gr-1 (Ly6C/Ly6G) RB6-8C5 141_Pr
CD11c N418 142_Nd
CD69 H1.2F3 145_Nd
CD45 30-F11 147_Sm
CD11b M1/70 148_Nd
CD19 6D5 149_Sm
CD25 3C7 151_Eu
CD3e 145-2C11 152_Sm
TER-119 TER119 154_Sm
CD62L MEL-14 160_Gd
CD8a 53-6.7 168_Er
TCRβ H57-597 169_Tm
NK1.1 PK136 170_Er
CD44 IM7 171_Yb
CD4 RM4-5 172_Yb
B220 Ra3-6B2 176_Yb
IFN-γ XMG1.2 165_Ho
IL-2 JES6-5H4 144_Nd
IL-4 11B11 166_Er
IL-5 TRFK5 143_Nd
IL-6 MP5-20F3 167_Er
IL-10 JES5-16E3 158_Gd
IL-17A TC11-18H10.1 174_Yb
TNFα MP6-XT22 162_Dy
Both the CD4+ and CD8+ T-cells were almost completely absent and the percentage of CD19+
B-cells decreased from 50% to 10% of CD45+ living singlets in the spleen of the 4T1 tumor bearing
mice (Figure 4D,E). The percentage of the myeloid CD11b+ cells increased from 10% to 80% at the
expense of lymphoid subsets due to breast cancer development (Figure 4D,E). Cisplatin treatment of
4T1 tumorous mice normalized the splenic immunophenotype similar to naive mice with 25% CD4+,
10% CD8+ T-cells, 40% CD19+ B-cells, and 20% CD11b+ cells (Figure 4F).
Int. J. Mol. Sci. 2020, 21, 170 7 of 19
Figure 4. Single cell mass cytometric immunophenotyping showed the accumulation of CD11b+
myeloid cells in 4T1 tumor bearing animals at the expense of lymphoid subsets which was reverted
by cisplatin treatment. The visualization of stochastic neighbor embedding (viSNE) analysis was run
on the (A) naive, (B) 4T1 tumor bearing, and (C) cisplatin treated 4T1 tumorous animals within the
CD45+ living singlets. Quantitative analysis of the main lymphoid subsets: CD4+ T-cells = lilac,
CD8+ T-cells = blue, CD19+ B-cells = orange and the myeloid CD11b+ = green, CD11c + = red subsets
were performed in the spleen of (D) naive, (E) 4T1 tumor bearing, and (F) cisplatin treated 4T1 tumorous
mice within the CD45+ living singlets. Representative viSNE plots and column bars are shown from the
pooled samples of 6 mice per group. Data are shown as arithmetic means on the column bars ± SEM.
Pairwise comparison of the emergence of CD11b+ population in (E) vs. (D) and its decrease by cisplatin
treatment (F) vs. (E) has statistical significance at p < 0.001.
The expression intensity of certain proteins within the viSNE plots of main subsets showed
dramatic changes (Figure 5). The expression pattern of Gr-1+ (Ly6C/Ly6G), CD44+, and IL-17A+ cells
within the cloud of CD11b+ myeloid cells were uniquely high in the spleen of 4T1 breast cancer bearing
mice (Figure 5) in accordance with the splenomegaly shown in Figure 2D. On the contrary, the B220 and
CD62L markers within the cloud of CD19+ B-cells, and the CD62L within the cloud of CD4+ and CD8+
T-cells also were highly reduced in the spleen of 4T1 tumorous mice (Figure 5). Cisplatin treatment
reverted the immunophenotype of both splenic CD11b+ myeloid (Gr-1+, CD44+ and IL-17A+) cells
and lymphoid (B220+/CD19+, CD62L+/CD19+, CD62L+/CD4+, CD62L+/CD8+ T-cells) cells similar to
naive mice (Figure 5).
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Figure 5. The viSNE plots illustrate the expression intensity of Gr-1, CD44, IL-17A, B220, CD62L
markers within the clouds of main subsets defined in Figure 4 in the splenic samples of naive, 4T1 tumor
bearing, and cisplatin treated 4T1 tumorous mice. The coloration is proportional to the expression
intensity (blue = low, red = high). The list of the antibodies can be found in Table 1 in Section 4.5.
Representative viSNE plots are shown from the pooled samples of 6 mice per group. The markers of
the panel which were not detected or did not show differential expression are not shown.
Quantitation of the populations with characteristic protein expression was performed by manual
gating within the CD45+ living singlets of splenocytes (Figure S3). The trajectories on the radar plots
delineate the characteristic marker profile of splenocytes of naive, 4T1 tumor bearing, and cisplatin
treated tumorous mice (Figure 6).
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Figure 6. The trajectories on the radar plots delineate the characteristic marker profile of splenocytes
in naive, 4T1 tumor bearing, and cisplatin treated tumorous mice. The accumulation of splenic (A)
CD11b+/Gr-1+ MDSCs, (B) CD44+, and in a smaller extent (C) IL-17A+ MDSCs is a characteristic of
4T1 breast cancer. Cisplatin restores the percentage of (D) B220+ and (E) CD62L+ B-cells, (F) CD62L+
CD4+ and (G) CD8+ T-cells. The percentage of the given populations is demonstrated on the radar
plots within the CD45+ living singlets determined by manual gating in Cytobank. The gating hierarchy
is explained in the text and in Figure S3. The markers of the panel which were not detected or did not
show differential expression are not shown. Representative radar plots are shown from the pooled
samples of 6 mice per group as described in Section 4.5.
MDSCs were defined as CD45+/CD3-/CD11+/Gr1+ cells and further evaluated for CD44 and
IL-17A staining. These MDSCs, CD44+ MDSCs and IL-17A+ MDSCs represented exclusively 60%,
60% and 6% of CD45+ living singlets in the spleen of 4T1 tumorous mice, respectively. The B-cell
marker B220 (except regulatory B-cells, germinal center B-cells, some plasma cells, and certain memory
B-cells [32–34]) on CD45+/CD3-/CD19+ B-cells was 40% in the naive, 30% in the cisplatin treated,
while only 6% in the untreated 4T1 tumorous mice. The homing receptor L-selectin, CD62L was almost
absent (0.2%) on the splenic B-cells of 4T1 tumorous mice but it was restored upon cisplatin treatment
to 5.5% (naive mice 12.5%). The CD45+/CD3+/TCRβ+/CD4+ and CD45+/CD3+/TCRβ+/CD8+ T-cells
expressed CD62L 15% vs. 20% and 6% vs. 10% in the splenocytes of naive and cisplatin treated 4T1
bearing mice, respectively. Sunburst charts represent the immunocomposition of main subsets of
the spleens detected by single cell mass cytometry in Figure S4A and FlowSOM (Flow data using
Self-Organizing Map, [35]) analysis demonstrates the identified clusters, minimum spanning trees
(MSTs) of splenic subsets in Figure S5.
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2.4.2. Cisplatin Could not Completely Restore the Peripheral Immunophenotye of 4T1 Tumor Bearing
mice but Increased IFN-γ Production of Myeloid Cells
Immunophenotype of the blood in breast cancer can reflect the state of the peripheral
tolerance associated with cancer-related inflammation or the activation of anti-tumor effector cellular
responses [36]. The viSNE plots of the main subsets in blood samples show the absence of peripheral
CD4+, CD8+ T-, and B-cells and the emergence of CD11b+ cells as a sign of advanced cancer compared
to naive blood (Figure 7A,B). Cisplatin treatment at least partially normalized the immunocomposition
of the blood of 4T1 tumorous mice (Figure 7C).
Figure 7. Immunophenotyping of blood showed dramatic expansion of CD11b+ cells in advanced
cancer. The viSNE analysis was run on the (A) naive, (B) 4T1 tumor bearing, and (C) cisplatin treated 4T1
tumorous animals within the CD45+ living singlets. Quantitative analysis of the main lymphoid subsets:
CD4+ T-cells = lilac, CD8+ T-cells = blue, CD19+ B-cells = orange and the myeloid CD11b+ = green,
CD11c + = red subsets was performed in the blood of (D) naive, (E) 4T1 tumor bearing, and (F) cisplatin
treated 4T1 tumorous mice within the CD45+ living singlets. Representative viSNE plots and column
bars are shown from the pooled samples of 6 mice per group. Data are shown as arithmetic means on
the column bars ± SEM. Pairwise comparison of the emergence of CD11b+ population in (E) vs. (D)
has significance at p < 0.001.
The percentage of CD11b+ cells of 4T1 tumor bearing mice due to advanced cancer-related
myeloid expansion represented around 97% (Figure 7E) in contrast to naive mice with 35% CD11b+
cells (Figure 7D) of CD45+ living singlets in the blood. The treatment of 4T1 breast cancerous mice
with cisplatin could not suppress the emergence of CD11b+ cells significantly with an average of
85% CD11b+ cells (Figure 7F). Myeloid expansion led almost to the absence of circulating T- and
B-lymphocytes in advanced cancer (Figure 7E). Cisplatin treatment at least partially restored the
percentage of these CD4+, CD8+ T- and CD19+ B-lymphocytes with an average 8.1% vs. 10.5%,
2.6% vs. 5.1%, 2.7% vs. 24.8% in naive mice, respectively (Figure 7D,F).
The differential expression intensity of the Gr-1, CD44, IFN-γmarkers on blood-derived leukocytes
was plotted on the viSNE graphs (Figure 8). Interestingly, the highest expression protein pattern of
Gr-1+/CD44+ (Gr-1+ bright/CD44+ bright) within the CD11b+ subset was associated with early cancer
disease in the blood of cisplatin treated 4T1 tumorous mice. The Gr-1+ dim/CD44+ dim immature
myeloid cells have been reported to suppress T-cells and IFN-γ production [37,38], the dim expression
intensity of these markers was characteristic to 4T1 tumor bearing mice (Figure 8). In line with
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this, the smaller population of IFN-γ producing myeloid cells appeared within the CD11 subtype by
cisplatin treatment which was completely absent in the advanced cancer (Figure 8).
Figure 8. The viSNE plots illustrate the expression intensity of Gr-1, CD44, and IFN-γ markers
within the clouds of main subsets defined in Figure 7 in the blood samples of naive, 4T1 tumor
bearing, and cisplatin treated 4T1 tumorous mice. The coloration is proportional with the expression
intensity (blue = low, red = high). The list of the antibodies can be found in Table 1 in the Section 4.5.
Representative viSNE plots are shown from the pooled samples of 6 mice per group. The markers of
the panel which were not detected or did not showed different expression are not shown.
Quantitation of the populations with characteristic protein expression was performed by manual
gating within the CD45+ living singlets of blood-derived leukocytes. The trajectories on the radar
plots delineate the characteristic marker profile of peripheral leukocytes of naive, 4T1 tumor bearing,
and cisplatin treated tumorous mice (Figure 9).
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Figure 9. The trajectories on the radar plots delineate the characteristic marker profile of blood-derived
leukocytes in naive, 4T1 tumor bearing, and cisplatin treated tumorous mice. The accumulation of
peripheral (A) CD11b+/Gr-1+ MDSCs and (B) CD44+ MDSCs is a characteristic of 4T1 breast cancer.
(C) Due to cisplatin treatment IFN-γ+ MDSCs were developed at the periphery. The percentage of the
given populations is demonstrated on the radar plots within the CD45+ living singlets determined by
manual gating in Cytobank. The gating hierarchy is explained in the text. The markers of the panel
which were not detected or did not show differential expression are not shown. Representative radar
plots are shown from the pooled samples of 6 mice per group as described in Section 4.5.
MDSCs were defined as CD45+/CD3-/CD11+/Gr1+ cells (Figure 9A) and further evaluated for
the expression of CD44 (Figure 9B) and IFN-γ (Figure 9C). The total MDSCs, CD44+ MDSCs and
IFN-γ + MDSCs represented 92%, 93%, and only 0.15% of CD45+ living singlets in the spleen of 4T1
advanced tumorous mice, respectively. Administration of cisplatin resulted in the decrease of the
percentage of both MDSCs, CD44+ MDSCs to 63% (naive blood 32%). Interestingly, IFN-γ which is
indispensable for antitumor immune response [39], was increased by cisplatin in 15% of MDSCs (naive
3%). Sunburst charts represent the immunocomposition of main subsets of the blood detected by
single cell mass cytometry in Figure S4B and FlowSOM (Flow data using Self-Organizing Map, [35])
analysis demonstrates the identified clusters, minimum spanning trees (MSTs) of peripheral subsets in
Figure S5.
3. Discussion
Solid tumors manifest when cancer cells escape from immunosurveillance. During cancer
development, malignant cells develop strategies to induce peripheral tolerance and in parallel
inflammatory cells change their phenotype to nurse the tumor and suppress anti-tumor effector
functions [36,40]. Since metastatic breast cancer is the most frequent and deadliest type of cancer
among young adult women [4,5], we focused on the 4T1 murine breast carcinoma model to study the
efficacy of anti-cancer drug candidates. Among chemotherapeutic compounds, cisplatin, a well-known
DNA crosslinker, a first line option in human carcinomas was investigated (as a reference drug) in
the 4T1 murine metastatic breast carcinoma model. This type of breast carcinoma can be a relevant
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animal model for the human disease because (i) it is orthotopically transplanted into the mammary
fat pad, (ii) it grows in immunocompetent mice (BALB/c) and (iii) gives metastasis spontaneously.
Here, we studied the immunophenotype of the spleen and blood of mice with advanced cancer and
with cisplatin treated cancer compared to naive mice.
We monitored the dose-response curve of cisplatin to 4T1 cells in real-time because previous
studies described results with endpoint assays [41–43]. The half maximal inhibitory concentration
(IC50) values showed time dependence: 36.74 µM at 24 h, 7.608 µM at 48 h, 6.962 µM at 72 h, 4.128 µM at
96 h, and 3.995 µM at 120 h (Figure 1 and Figure S1). In order to investigate the alteration of the tumor
stroma or the immunophenotype changes during cancer development the 4T1 cells were orthotopically
injected into BALB/c mice. Cisplatin reduced the tumor growth, the number of lung metastatic nodules,
and splenomegaly (Figure 2). In addition to malignant cells, the alteration of the stroma of solid tumors,
namely the activation of cancer-associated fibroblasts has been described as critical determinant of
cancer development and survival, and was also confirmed as therapeutic target [2]. It was shown
that the expression of FAP prolyl endopeptidase, even on the cell surface or solubilized in the plasma,
correlates with the malignancy and cisplatin resistance of carcinomas [29,44–46]. Therefore, we have
developed an assay to measure the activity of FAP cleaving the Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2
peptide substrate (Figure S2). We could show that cisplatin treatment significantly reduced the FAP
activity of the plasma of 4T1 tumor bearing mice (Figure 3).
It has been widely known that the alternative polarization of the immune system, the accumulation
of immature myeloid cells (MDSCs) with potent immunosuppression contribute to the cancer
development [12,47]. The splenic immunophenotye of mice with advanced cancer showed the
emergence of the hyaluronic acid receptor CD44+ and in a smaller extent IL-17A+ MDSCs,
the loss of B220+ and CD62L+ B-cells, the loss of CD62L+ CD4+ and CD8+T-cells (Figures 5–7).
Myeloid expression of IL-17A in the spleen has been published as a sign of advanced cancer [26].
Cisplatin treatment could restore the splenic immunophenotype downregulating CD44+, IL-17A+
MDSCs presumably because of the smaller tumor burden, on the other hand MDSCs are also sensitive
to low dose chemotherapy due to their high proliferative potential [30]. The blood showed the
expression of Gr-1+dim, more immature MDSCs in advanced cancer (Figure 8), which has been
reported to suppress T-cell proliferation and IFN-γ production [37]. The expression intensity of
CD44 on circulating MDSCs was also dim suggesting more immature phenotype (Figure 8), however,
the percentage of CD44+MDSCs (irrespective of the CD44 marker intensity) was higher in the
blood of mice with advanced cancer (Figure 9). Cisplatin partially reduced the accumulation of
CD44+/CD11+/Gr1+ myeloid cells in the circulation, but changed their phenotype via induction of
INF-γ production (Figure 9). It has been reported that IFN-γ producing immature myeloid cells could
exert a potent immune response against sever invasive bacterial infections [48]. Computational tools,
unsupervised algorithms were used to summarize our results, such as sunburst population analysis in
Figure S4 and the FlowSOM analysis in Figure S5.
The immunomodulatory effect of cisplatin by increasing tumor immunogenicity has been recently
published in ovarian cancer [22]. The general overview of chemotherapeutics, especially cisplatin
mediated immunomodulation has been reviewed elsewhere [49,50].
To the best of our knowledge our study is the first using single cell mass cytometry to show the
immunomodulatory effect of cisplatin in the 4T1 murine model of metastatic triple negative breast
cancer via downregulation of immature myeloid cells and upregulation of CD62L+ B- and T-cells and
IFN-γ+ peripheral myeloid cells.
4. Materials and Methods
4.1. Real-Time Cell Electronic Sensing (RT-CES) Cytotoxicity Assay
The 4T1 cells were purchased from the ATCC (American Type Culture Collection, Manassas, VA,
USA) and maintained as described previously [10]. Briefly, 4T1 were maintained in Roswell Park
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Memorial Institute 1640 medium (RPMI-1640) with 10% FCS. The pH of the cell culture media was
controlled to be between 7.2–7.4 prior use. The medium was supplemented with 2 mM GlutaMAX,
and 100 U/mL penicillin, 100 µg/mL streptomycin (Life Technologies, Carlsbad, CA, USA) before use.
Cells were passed every three days and placed in a humidified incubator at 37 ◦C 5% CO2 (Sanyo, Osaka,
Japan). The xCelligence real-time cell electronic sensing (RT-CES) cytotoxicity assay (Acea Biosciences,
San Diego, CA, USA) was performed as previously described with some modifications [25,51].
Briefly, 96-well E-plate (Acea Biosciences) was coated with gelatin solution (0.2% in phosphate buffered
saline, PBS) for 20 min at 37 ◦C, then gelatin was washed twice with PBS solution. Growth media
(50 µL) was then gently dispensed into each well of the 96-well E-plate for background readings by the
RT-CES system prior to addition of 50 µL of the cell suspension containing 2 × 104 4T1 cells. Plates
were kept at room temperature in a tissue culture hood for 30 min prior to insertion into the RT-CES
device in the incubator to allow cells to settle. Cell growth was monitored for 48 h by measurements
of electrical impedance every 15 min. Continuous recording of impedance in cells was reflected by
cell index value. 48 h later cells were treated with an increasing concentration (134 nM–100 µM)
of cisplatin (Selleckchem, Houston, TX, USA), treatments are demonstrated between 3.704–100 µM.
Treated and control wells were dynamically monitored over 120 h by measurements of electrical
impedance every 15 min. The raw plate reads for each titration point were normalized relative to
the cell index status right before treatment. Each treatment was repeated in 3 wells per plate during
the experiments. The half maximal inhibitory concentration (IC50) was calculated with relation to
untreated control cells (1 corresponds to 100% viability on the y axis), and blank wells containing
media without cells. IC50 values (50% inhibiting concentration) were calculated by GraphPad Prism®
(version 5.01, La Jolla, CA, USA).
4.2. The 4T1 in Vivo Breast Carcinoma Model
The animal experiments were performed in accordance with animal experimentation and
ethics guidelines of the EU (2010/63/EU). Experimental protocols were approved by the responsible
governmental agency (National Food Chain Safety Office) in possession of an ethical clearance
XXIX./128/2013.
Female Charles River-derivative BALB/c mice (8–10 week old) were purchased from Kobay Ltd.,
(Ankara, Turkey) and were injected orthotopically with 4T1 breast carcinoma cells (1.2 × 105 cells)
as described previously [9]. The animals had free access to food and water. Six mice were included
into each experimental group. Treatment by cisplatin (Ebewe Pharma, Unterach am Attersee, Austria)
was started after 10 days of inoculation and followed in every 5th day in 5 mg/kg dose administered
intraperitoneally twice on the day of the treatment. The experiments were repeated independently
two times under the same conditions, the pooled results have been presented in the paper (n = 12).
Tumors were evaluated macroscopically by the following parameters: 1) incidence of palpable tumors
was determined by the daily monitoring of animals in each experimental group; 2) tumor size was
measured with a precision caliper and calculated according to the formula: d2 × D × 0.5, where d and
D are the minor and major diameters, respectively; 3) after euthanizing the animals, weights of the
excised primary tumors, spleens, and lungs were measured. Spleen and blood were processed freshly
in order to isolate leukocytes. Mice showing signs of suffering (lost 15% of body weight and/or loss of
the righting reflex and/or enable to eat, drink) due to (ethical) legislation were sacrificed.
4.3. Synthesis of Fmoc-Gly-Pro-Cysteic Acid-Ile-Gly-NH2 Peptide
In order to obtain the target peptide, Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2,
first Fmoc-Gly-Pro-Cys-Ile-Gly-NH2 peptide was synthesized (Fmoc, 9-fluorenylmethoxycarbonyl,
Avidin Ltd., Szeged, Hungary). Reagents, otherwise not stated, were purchased from Sigma-Aldrich
(St. Louis, MI, USA). Fmoc-strategy synthesis was carried out manually in a solid-phase vessel on
Rink Amide ChemMatrix resin, the protected Fmoc-amino acids (3 equiv.) were coupled using
DCC (dicyclohexylcarbodiimide 3 equiv.) and HOBt (1-hydroxybenzotriazole, 3 equiv.) in DMF
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(N,N-dimethylformamide) for 2 h at room temperature. The deprotection of the Fmoc-group
was achieved with the treatment of the resin with 5% piperazine/DMF (1 × 5 min, 1 × 20 min).
Washings between coupling and deprotection were performed with DMF (3 × 1 min), MeOH
(methanol) (1 × 1 min) and DMF (3 × 1 min). The completion of the coupling was monitored
using the Kaiser test. Following the final coupling, the resin was washed with DMF (3 × 1 min)
and MeOH (3 × 1 min), and dried under a stream of air. The dry resin was treated with TFA/H2O
(trifluoroacetic acid/H2O, 95:5) for 3 h at room temperature. The cleavage mixture was lyophilized, and
the pellet was redissolved in MeOH/AcN (methanol/acetonitrile, 1:1) for Liquid chromatography-mass
spectrometry (LC-MS) analysis (Agilent, Santa Clara, CA, USA). The LC-MS analysis found that
Fmoc-Gly-Pro-Cys-Ile-Gly-NH2 was obtained in 90% purity (linear gradient from 0% to 100% AcN
over 30 min, tR: 21.77 min). LC-MS observed [M + H]+ 667.2, required [M + H]+ 667.8. The obtained
Fmoc-Gly-Pro-Cys-Ile-Gly-NH2 was transformed into Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2 peptide
with no further purification. It was dissolved in acetone, cooled to 1 ◦C in a mixture of ice and
water. First 30% aqueous H2O2 was added, then Na2WO4.2H2O in catalytic amount. After 3 h,
we did not detect the starting material (Fmoc-Gly-Pro-Cys-Ile-Gly-NH2), it completely transformed
into the desired Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2 peptide. The LC-MS analysis found that
Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2 was obtained in 75% purity (linear gradient from 0% to 100%
AcN over 30 min, tR: 16.90 min). LC-MS observed [M + H]+ 715.2, required [M + H]+ 715.8. To purify
the crude peptide, it was dissolved in AcN/MeOH/H2O, then filtered, using a 0.45 µm nylon filter.
Gradient elution was used, 70–100% AcN in 60 min at a 3 mL min-1 flow rate with detection at 220 nm.
Pure fractions were collected and lyophilized to give a fluffy white material.
4.4. FAP Activity Assay
Blood from control and tumor bearing (untreated and cisplatin treated) BALB/c mice was
drawn (200 µL) into EDTA containing tubes (separately from 3 animals from each group).
Reagents, otherwise not stated, were purchased from Sigma-Aldrich. Blood samples were centrifuged
at 12,000 RPM for 10 min. Supernatant (plasma) was removed and transferred to fresh tubes and were
immediately used. Digestion reactions were set up by combining 36 µL plasma and 9 µL solution
of cysteine acid containing peptide solution (5 mg/mL) for a final peptide concentration of 1 mg/mL.
Reactions were incubated at 37 ◦C for 60 min. After incubation, 75 µL of acetonitrile containing 0.2%
trifluoro-acetic (TFA) acid was added and samples were centrifuged at 12,000 RPM for 5 min. 80 µL
of supernatant was removed and transferred to fresh tubes and were stored at −20 ◦C until analysis.
Area under the curve (AUC) values of the peptide digestion product 2 were plotted.
4.5. Mass Cytometry
Single cell mass cytometry (CyTOF, Fluidigm, San Francisco, CA, USA)) was performed as
described previously with some modifications [52]. Briefly, naive, 4T1 breast tumor bearing and
cisplatin treated 4T1 tumor bearing mice were euthanized on the 23rd day after 4T1 injection. Spleen and
blood were processed freshly. Withdrawal of the blood was carried by cardiac puncture using 50 µL
EDTA (30 mg/mL) per syringe (Beckton Dickinson, Franklin Lakes, NY, USA). Spleen was smashed on
100 µm cell strainer (VWR, Radnoe, PA, USA), washed with PBS and centrifuged at 1400 rpm 5 min.
Blood was centrifuged at 2000 rpm for 10 min, plasma was harvested and stored at −80 ◦C. Both the
pellet of spleen and blood were resuspended. Red blood cell lysis was carried out by the incubation
of cells with 5 mL ACK (0.155 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.3, Sigma-Aldrich)
solution for 5 min. Samples were loaded on cell strainer (70 µm in pore size,) and washed by 20 mL
PBS. Cells were counted using Bürker chamber and trypan blue viability dye. Three million cells
were pooled from six mice per group for mass cytometry (Helios, Fluidigm, San Francisco, CA, USA).
The in vivo experiment and CyTOF were repeated twice. Cells viability was determined by cisplatin
(5 µM 195Pt, Fluidigm) staining for 3 min on ice in 300 µL PBS. Sample was diluted by 1500 µL Maxpar
Cell Staining Buffer (MCSB, Fluidigm) and centrifuged at 350 g for 5 min. Cells were suspended in
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50 µL MCSB and the antibody mix (Table 1) was added in 50 µL (each antibody diluted finally 1:100).
Two commercially available antibody panel was combined, the Maxpar® Mouse Sp/LN Phenotyping
Panel kit (Fluidigm, cat. numbers 201306) and Maxpar® Mouse Intracellular I Cytokine Panel kit
(Fluidigm, cat. number 201310).
Samples after 60 min incubation at 4 ◦C, antibodies were washed by 2 mL MCSB and centrifuged
at 300 g 5 min, two times. The pellet was suspended in the residual volume. Cells were fixed in 1.6%
formaldehyde (freshly diluted from 16% Pierce formaldehyde with PBS, Thermo Fisher Scientific,
Waltham, MA, USA) and incubated for 10 min at room temperature. Cells were centrifuged at 800 g for
5 min. Cell ID DNA intercalator (125 µM, 191/193 Iridium, Fluidigm) was added in 1000× dilution in
Maxpar Fix and Perm for overnight at 4 ◦C. Cells for the acquisition were centrifuged at 800g for 5 min
then were washed by 2 mL MCSB and centrifuged at 800 g for 5 min. Cells were suspended in 1 mL
PBS (for WB injector) and counted in Bürker-chamber during centrifugation. For the acquisition the
concentration of cells was set to 0.5 × 106/mL in cell acquisition solution (CAS, Fluidigm) containing
10% EQ Calibration Beads. Cells were filtered through 30 µm Celltrics gravity filter (Sysmex, Görlitz,
Germany) and acquired freshly. Mass cytometry data were analyzed in Cytobank (Beckman Coulter,
Brea, CA, USA). Single living cells were determined. The viSNE analysis was carried-out (iterations
= 1000, perplexity = 30, theta = 0.5) on 5 × 104 for the spleen and 2 × 104 for blood of CD45+ living
singlets. Reduction of dimensionality was performed by FlowSOM also, by an algorithm creating
self-organizing maps during automated clustering in Cytobank [35].
4.6. Statistical Analysis
Results are shown as arithmetic mean ± standard error of the mean (SEM); statistical comparisons
were performed by two-tailed Student’s t-test as pairwise comparisons as described in the figure
legends. In all statistical comparisons, probability “p” was set as the level of significance (set at
* p < 0.05, ** p < 0.01, ***, p < 0.001). Data were processed and analyzed using Microsoft Excel (Microsoft
Office 2016, Redmond, WA, USA), and visualized using GraphPad Prism or Cytobank.
5. Conclusions
Our findings showed that cisplatin treatment reduced tumor growth, number of lung metastasis
and the splenomegaly of 4T1 tumor bearing mice. Cisplatin inhibited the tumor stroma formation,
the activation of carcinoma-associated fibroblasts by the diminished proteolytic activity of fibroblast
activating protein. Single cell mass cytometry revealed that cisplatin could exert a potent
immunomodulatory effect via inhibiting the accumulation of splenic MDSCs in a murine model
of metastatic triple negative breast cancer. Emergence of certain myeloid subsets in the spleen,
such as CD44+MDSCs and IL-17A+MDSC were associated with advanced cancer, while within the
lymphoid subsets, the absence the B220+ B-cells, CD62L+ B-cells, CD62L+CD4+ T-cells, and CD62L+
CD8+ T-cells was shown in the untreated tumor bearing mice. However, cisplatin treatment could
restore the splenic immunophenotype similar to naive mice. Peripheral MDSCs in the circulation
were not completely eliminated by cisplatin but myeloid-derived IFN-γ production was increased.
Thus, our study highlights the use of low-dose chemotherapy, such as cisplatin in combination with
immunotherapies to treat triple negative breast cancer.
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